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Brian K Hubbard **, Michael G Thomas ** and Christopher T Walsh
Background: The non-proteinogenic amino acid p-hydroxyphenylglycine is a
crucial component of certain peptidic natural products synthesized by a non-
ribosomal peptide synthetase mechanism. In particular, for the vancomycin group
of antibiotics p-hydroxyphenylglycine plays a structural role in formation of the
rigid conformation of the central heptapeptide aglycone in addition to being the
site of glycosylation. Initial labeling studies suggested tyrosine was a precursor of
p-hydroxyphenylglycine but the speci¢c steps in p-hydroxyphenylglycine
biosynthesis remained unknown. Recently, the sequencing of the
chloroeremomycin gene cluster from Amycolatopsis orientalis gave new insights
into the biosynthetic pathway and allowed for the prediction of a four enzyme
pathway leading to L-p-hydroxyphenylglycine from the common metabolite
prephenate.
Results: We have characterized three of the four proposed enzymes of the L-p-
hydroxyphenylglycine biosynthetic pathway. The three enzymes are encoded by
open reading frames (ORFs) 21, 22 and 17 (ORF21: [PCZA361.1, O52791,
CAA11761]; ORF22: [PCZA361.2, O52792, CAA11762]; ORF17: [PCZA361.25,
O52815, CAA11790]), of the chloroeremomycin biosynthetic gene cluster and we
show they have p-hydroxymandelate synthase, p-hydroxymandelate oxidase and
L-p-hydroxyphenylglycine transaminase activities, respectively.
Conclusions: The L-p-hydroxyphenylglycine biosynthetic pathway shown here is
proposed to be the paradigm for how this non-proteinogenic amino acid is
synthesized by microorganisms incorporating it into peptidic natural products. This
conclusion is supported by the ¢nding of homologs for the four L-p-hydroxy-
phenylpyruvate biosynthetic enzymes in four organisms known to synthesize
peptidic natural products that contain p-hydroxyphenylglycine. Three of the
enzymes are proposed to function in a cyclic manner in vivo with L-tyrosine being
both the amino donor for L-p-hydroxyphenylglycine and a source of
p-hydroxyphenylpyruvate, an intermediate in the biosynthetic pathway.
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Introduction
One of the hallmarks of peptidic natural products synthe-
sized by non-ribosomal peptide synthetases (NRPSs) is the
incorporation of non-proteinogenic amino acids into the
antibiotic products. Selection, activation and incorporation
of these unusual amino acids is a central mechanism by
which NRPS synthesized peptides achieve the remarkable
structural diversity that contributes to their wide assort-
ment of biological activities [1^3]. These activities range
from antimicrobial, antiviral and immunosuppressive activ-
ities to specialized functions as iron chelators and biosur-
factants. The unusual, non-proteinogenic amino acid moi-
eties may arise from the incorporation of a natural,
proteinogenic amino acid into the growing peptidyl chain
by the NRPS, followed by downstream modi¢cation of the
residue by epimerization, N-methylation, cyclization or ox-
idation to name a few of the observed modi¢cations [1^3].
Alternatively, the non-proteinogenic amino acid may be
synthesized by a novel, dedicated biosynthetic pathway
to provide the monomer to the particular NRPS assembly
line. Once incorporated into the growing peptidyl chain,
additional modi¢cations may be catalyzed by the NRPS.
The non-proteinogenic amino acid p-hydroxyphenylgly-
cine is found in several peptidic natural products including
the vancomycin group of antibiotics (e.g. vancomycin [4],
chloroeremomycin [5], A47934 [6], and complestatin [7,8])
as well as other antimicrobial compounds such as ramopla-
nin [9] and calcium-dependent antibiotic [10] (Figure 1).
For members of the vancomycin group of antibiotics,
p-hydroxyphenylglycine residues play crucial roles in the
structure and function of the ¢nal glycopeptide antibiotic.
In vancomycin and chloroeremomycin, the D-p-hydroxy-
phenylglycine at residue four of the heptapeptide is oxida-
tively cross-linked with the aryl rings of the L-hydroxyty-
rosines at positions two and six, creating part of the rigid
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scaffold characteristic of these antibiotics. Analogously, the
D-p-hydroxyphenylglycine at residue ¢ve is oxidatively
crosslinked to the 3,5-dihydroxy-L-phenylglycine at residue
seven, completing the rigid scaffold (Figure 1). Finally, the
D-p-hydroxyphenylglycine of residue four of the cross-
linked aglycone is also the site of glycosylation as sugars
are added to create the ¢nal antibiotics. The committed
synthesis of p-hydroxyphenylglycine and clustering the
genes encoding enzymes for its proposed biosynthetic
pathway with other enzymes in vancomycin assembly sug-
gests this residue provides reactivity and/or architecture
not available in the proteinogenic homolog tyrosine. The
Figure 1. Chemical structures of representative p-hydroxyphenylglycine-, highlighted in red, containing peptidic natural products. For
calcium-dependent antibiotic (CDA): CDA1: R1 = OPO3H2, R2 = H; CDA2: R1 = OPO3H2, R2 = CH3; CDA3b: R1 = OH, R2 = H; CDA4b:
R1 = OH, R2 = CH3) [10].
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essential nature of this hydroxyaryl amino acid in the core
structure of vancomycin group antibiotics suggests knowl-
edge of the biosynthetic pathway is important for future
efforts in combinatorial biosynthetic manipulation.
Proposals for p-hydroxyphenylglycine biosynthesis for van-
comycin group antibiotics have been based on labeling
studies where either [13C]tyrosine or [2H,13C]tyrosine was
fed to growing cultures and analysis of the ¢nal glycopep-
tide product showed incorporation of label into the D-p-
hydroxyphenylglycine residues leading to the conclusion
that p-hydroxyphenylglycine is derived from tyrosine
[11^14]. Recently, new insights into p-hydroxyphenylgly-
cine biosynthesis came from the sequencing of the chloro-
eremomycin biosynthetic gene cluster from Amycolatopsis
orientalis [15] (Figure 2a). In this gene cluster, four open
reading frames (ORFs) could be assigned to genes encod-
ing enzymes with putative functions for p-hydroxyphenyl-
glycine biosynthesis. These four ORFs (1, 17, 21, 22)
(ORF1: [PCZA363.1, 052817, CAA11792.1]; ORF21:
[PCZA361.1, O52791, CAA11761]; ORF22: [PCZA361.2,
O52792, CAA11762]; ORF17: [PCZA361.25, O52815,
Figure 2. (a) Diagram of the genes encoded in the chloroeremomycin biosynthetic cluster. Numbers indicate the ORF starting with the ¢rst
gene of the gene cluster. Cep A, B and C are the NRPS encoding genes [15]. (b) Outline of proposed biosynthetic pathway for the non-
proteinogenic amino acid L-p-hydroxyphenylglycine.
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CAA11790]) can be organized into a biosynthetic pathway,
whereby p-hydroxyphenylglycine biosynthesis can begin
not only with tyrosine as previously proposed, but also
with prephenate, a common precursor for L-phenylalanine
and L-tyrosine biosynthesis (Figure 2b).
Here, we present the puri¢cation and initial biochemical
characterization of ORFs 17, 21 and 22 of the chloroere-
momycin biosynthetic gene cluster and de¢ne their enzy-
matic roles in the biosynthesis of L-p-hydroxyphenylgly-
cine.
Results
Expression and puri¢cation of the enzymes of the
L-p-hydroxyphenylglycine biosynthetic pathway
Analysis of the chloroeremomycin biosynthetic cluster of A.
orientalis identi¢ed four ORFs that could be organized into
a putative L-p-hydroxyphenylglycine biosynthetic pathway
based on amino acid sequence homologies. The candidates
for this pathway were ORFS 1, 17, 21 and 22, which have
the proposed functions of prephenate dehydrogenase, L-
tyrosine:p-hydroxybenzoylformate transaminase, p-hydroxy-
phenylpyruvate dioxygenase and L-p-hydroxymandelate
oxidase, respectively (Figure 2b). To assess the validity
of this proposed pathway, each of the candidate ORFs
was cloned and the encoded protein was overexpressed
in Escherichia coli for initial biochemical characterization.
ORF1 is homologous to prephenate dehydrogenases and
is anticipated to generate p-hydroxyphenylpyruvate from
prephenate. Attempts to obtain soluble protein for bio-
chemical characterization have been unsuccessful to date.
We therefore focused on the three remaining ORFs of the
pathway and as shown in Figure 3, all three could be
puri¢ed with af¢nity tags to near homogeneity based on
sodium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE) analysis.
Characterization of ORF21 as an iron-dependent
p-hydroxyphenylpyruvate decarboxylating hydroxylase
that produces L-p-hydroxymandelate
ORF21, af¢nity-tagged with 10 histidine residues at its
amino terminus, was puri¢ed in the apo form with a pro-
tein yield of 10 mg/l. The apo form of ORF21 was inactive,
but holo-ORF21 could be reconstituted by preincubation
of the enzyme with excess FeCl2 immediately before use.
This resulted in Fe3 holo-enzyme that was inactive until
the iron was reduced to Fe2 by ascorbic acid that was
present in the reaction mixture.
Based on amino acid sequence homology, ORF21 was an-
ticipated to encode a p-hydroxyphenylpyruvate dioxygen-
ase, a member of the K-keto acid-dependent non-heme
iron-dependent dioxygenase family of enzymes [16].
ORF21 shows 28% identity and 44% similarity, at the ami-
no acid level, with the p-hydroxyphenylpyruvate dioxygen-
ase from Pseudomonas £uorescens, the structure of which has
recently been reported [17]. Additionally, ORF21 retains
42 of the 54 amino acid residues conserved in all p-hy-
droxyphenylpyruvate dioxygenases from both eucaryotes
and procaryotes [17]. p-Hydroxyphenylpyruvate dioxygen-
ases are non-heme iron dioxygenases that catalyze the
conversion of p-hydroxyphenylpyruvate to homogentisate
during oxidative tyrosine degradation (reviewed in [16]).
It was our expectation that ORF21 would use p-hydroxy-
phenylpyruvate, putatively provided by the action of
ORF1, and convert it not to homogentisate, but rather to
p-hydroxymandelate (Figure 4a). To test this hypothesis of
novel regiospeci¢city, holo-ORF21 was incubated with
p-hydroxyphenylpyruvate and the product of the reaction
was analyzed by high performance liquid chromatography
(HPLC) (Figure 4b). This analysis revealed the complete
conversion of the K-keto acid substrate to a product that
was distinct from homogentisate. Furthermore, the product
eluted from the HPLC with a retention time equal to that
seen for authentic p-hydroxymandelate (Figure 4b). Coin-
jection of the reaction product with commercially available
p-hydroxymandelate resulted in the elution of a single
peak from the HPLC (data not shown), providing further
support for the conclusion that ORF21 catalyzes the con-
version of p-hydroxyphenylpyruvate to p-hydroxymande-
late. The hydroxylation is likely to be stereospeci¢c based
on the speci¢city of ORF22 for L-p-hydroxymandelate (see
below) and validation of this proposal was provided by in
situ coupling of ORF21 and ORF22 (discussed below).
While this manuscript was being submitted, Choroba et
al. published a communication on ORF21 [18], indepen-
dently establishing some of the results discussed here. To
stay consistent with their recommended nomenclature,
ORF21 is referred to as 4-hydroxymandelate synthase
(HmaS).
Figure 3. SDS^PAGE gel showing the puri¢ed protein
preparations of ORF21/His, ORF22/MBP and ORF17/MBP. Lane
1: Molecular weight markers, lane 2: ORF21/HIS, lane 3: ORF22/
MBP, lane 4: ORF17/MBP.
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Characterization of ORF22 as a hydroxymandelate
oxidase (Hmo), an FMN containing enzyme
Expression of ORF22
The predicted reaction for Hmo is the oxidation of p-hy-
droxymandelate to give p-hydroxybenzoylformate. Hmo
shares amino acid sequence homology to the FMN con-
taining glycolate oxidase (GO) and mandelate dehydroge-
nase (MDH) (50 and 52% amino acid sequence identity,
respectively). MDH catalyzes the oxidation of L-mandelate
to yield benzoylformate using FMN as a cofactor. Both GO
and MDH contain FMN when puri¢ed from overexpres-
sion in E. coli [19].
The gene encoding Hmo was initially cloned into the pro-
tein expression plasmid pET-16b, resulting in an amino-
terminal decahistidyl-tagged Hmo. Expression of Hmo in
pET-16b yielded large quantities of soluble protein. How-
ever, after puri¢cation of the soluble, af¢nity-tagged Hmo
by nickel chelate chromatography using standard condi-
tions, the puri¢ed enzyme did not show UV/Vis absorbance
at 375 or 480 nm (the usual absorbance of FMN; data not
shown), suggesting the FMN cofactor was removed during
puri¢cation. Consistent with that conclusion, no activity
could be detected for the oxidation of D,L-p-hydroxyman-
delate by this puri¢ed enzyme. Furthermore, the addition
of exogenous FMN to the enzyme did not result in detect-
able oxidation of p-hydroxymandelate.
It was assumed that puri¢cation of this enzyme under the
conventional high salt conditions for poly-his-tagged pro-
teins resulted in the irreversible release of the FMN from
the enzyme. As an alternative puri¢cation procedure, Hmo
was cloned into a vector that introduced an amino-terminal
maltose binding protein (MBP) af¢nity tag that allowed
puri¢cation of the MBP^Hmo fusion protein under low
salt conditions (see Materials and Methods). The resulting
protein was yellow and showed a UV/Vis absorbance spec-
trum typical of FMN containing enzymes (data not
shown). The MBP^Hmo protein was used for all assays
listed below.
Activity of ORF22
The Hmo catalyzed oxidation of p-hydroxymandelate was
detected by UV/Vis assays using potassium ferricyanide as
electron acceptor [19]. HPLC assays of Hmo activity, after
exhaustive incubation with substrate, showed that half of
the D,L-p-hydroxymandelate was converted to a new prod-
uct (Figure 5) that decomposed with time. Mass spectral
analysis of this product showed the compound to have a
mass of 166 (data not shown), consistent with the product
being p-hydroxybenzoylformate, as predicted (Figure 5).
The secondary products of the reaction were not analyzed
but are presumed to result from decarboxylation of p-hy-
droxybenzoylformate.
Figure 4. (a) Comparison of the reaction catalyzed by
p-hydroxyphenylpyruvate dioxygenase versus the reaction
proposed to be catalyzed by ORF21. (b) HPLC traces of products
from the following reactions: 1, p-hydroxyphenylpyruvate standard;
2, p-hydroxymandelate standard; 3, homogentisate standard
and 4, complete reaction mixture (ORF21 plus p-hydroxyphenyl-
pyruvate), highlighted in red. Each peak is identi¢ed by the
chemical structure of the corresponding compound. For each
of the standards, ORF21 was inactivated by TFA addition prior
to addition of standard compound. The peak at 11.3 min is due
to ascorbic acid, the reductant used in all ORF21 assays
(data not shown).
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Since half of the D,L-p-hydroxymandelate was converted to
product in the Hmo catalyzed reaction, we sought to de-
termine the enzyme speci¢city for the D- or L-isomer (the
presumed product of the HmaS reaction). Both authentic
D- and L-mandelate were tested as substrates and HPLC
traces showed that only L-mandelate was converted to a
product that eluted from the HPLC with a retention
time consistent with benzoylformate (Figure 6). The prod-
uct of the Hmo/L-mandelate reaction coeluted from the
HPLC with authentic benzoylformate. By extension we
assigned L-p-hydroxymandelate as the substrate for Hmo.
When Hmo was assayed in conjunction with HmaS, the
product of the HmaS reaction (p-hydroxymandelate) was
converted to p-hydroxybenzoylformate by Hmo (Figure 7).
Since L-p-hydroxymandelate was the substrate for Hmo
and nearly all the HmaS generated product was converted
by Hmo, the product of HmaS is L-p-hydroxymandelate as
seen in Figure 7a.
Characterization of ORF17 as a p-hydroxyphenylglycine
transaminase (HpgT)
Expression of ORF17
ORF17 shows protein sequence homology to a number of
amino acid transaminases and was hypothesized to be a
HpgT catalyzing the conversion of p-hydroxybenzoylfor-
mate to L-p-hydroxyphenylglycine. The gene was cloned
and the enzyme was expressed as an amino-terminal MBP
fusion protein, similar to the procedure used for Hmo.
Following puri¢cation, the protein did not contain the pro-
posed coenzyme, pyridoxal phosphate (PLP). Exogenous
PLP was required for HpgT catalytic activity and was
added to the reaction mixtures for the assays described
below.
Characterization of the HpgT reaction
The conversion of L-p-hydroxyphenylglycine (the pre-
sumed product of the enzyme) to p-hydroxybenzoylfor-
mate in the presence of various common K-keto acids as
amino acceptors was used as the initial characterization of
HpgT. In this ‘reverse direction’ assay L-p-hydroxyphenyl-
glycine was used as the amino donor in conjunction with
the common K-keto acids, glutamate, pyruvate and oxalo-
acetate, as well as p-hydroxyphenylpyruvate, an intermedi-
ate from the p-hydroxyphenylglycine biosynthetic route, as
amino acceptors. The reactions demonstrated that only
p-hydroxyphenylpyruvate was able to function as a cosub-
strate for HpgT catalyzed conversion of L-p-hydroxyphe-
nylglycine to p-hydroxybenzoylformate. Previous feeding
experiments demonstrated that radiolabeled L-p-hydroxy-
phenylglycine and D-p-hydroxyphenylglycine were incor-
porated into mature vancomycin [11,12]. To determine if
L-p-hydroxyphenylglycine and/or D-p-hydroxyphenylgly-
cine were the product of the amino transferase reaction,
L- and D-p-hydroxyphenylglycine were used in an assay
with glutamate, pyruvate, oxaloacetate or p-hydroxyphenyl-
pyruvate as amino acceptors. Only the combination of L-p-
hydroxyphenylglycine and p-hydroxyphenylpyruvate gave
two new products, p-hydroxybenzoylformate and tyrosine.
This demonstrated that p-hydroxybenzoylformate and ty-
rosine were interconverted with L-p-hydroxyphenylglycine
and p-hydroxyphenylpyruvate by HpgT (Figure 8a,b).
To demonstrate that the product of the Hmo reaction was
converted to L-hydroxyphenylglycine, the ‘forward direc-
tion’ assay, a reaction with p-hydroxymandelate, L-tyrosine,
Figure 5. HPLC trace of Hmo catalyzed reaction. A: Authentic
D,L-p-hydroxymandelate. B: Hmo catalyzed reaction with D,L-p-
hydroxymandelate showing the production of p-hydroxy-
benzoylformate.
Figure 6. HPLC trace of the Hmo catalyzed reaction with D- and
L-mandelate. A: Authentic mandelate. B: Authentic
benzoylformate. C: Reaction of Hmo with D-mandelate.
D: Reaction of Hmo with L-mandelate showing the formation of
benzoylformate.
CHBIOL 42 13-3-01 Cyaan Magenta Geel Zwart
936 Chemistry & Biology 2000, Vol 7 No 12
Hmo and HpgT, was carried out and monitored by HPLC.
Half of the p-hydroxymandelate was converted to p-hy-
droxyphenylglycine, as determined by co-migration with
authentic L-p-hydroxyphenylglycine and p-hydroxyphenyl-
pyruvate (Figure 9). The conversion of the Hmo product
to the substrate for HmaS establishes a three enzyme
cycle, catalytic in p-hydroxyphenylpyruvate (Figure 10).
Substrate speci¢city for HpgT
To determine substrate speci¢city of HpgT, the reactions
listed in Table 1 were performed. These results imply the
reactivities shown in Figure 9, where the p-hydroxyl group
on the amino donor or amino acceptor is not a stringent
requirement, and 3-Cl-L-tyrosine is also accepted as an
amino donor. This implies a promiscuity by the HpgT.
Since many of the glycopeptide antibiotics contain mono-
and dichloro-hydroxyphenylglycine, it is possible that this
HpgT is involved in the biosynthesis of the chlorinated
analogues.
Discussion
The non-proteinogenic amino acid p-hydroxyphenylgly-
cine is incorporated into various peptidic natural products
such as the vancomycin group of antibiotics, ramoplanin
and calcium-dependent antibiotic. The presence of a
non-proteinogenic amino acid, such as p-hydroxyphenyl-
glycine, in a peptidic natural product strongly suggests
that the molecule has an NRPS component to its biosyn-
thetic pathway. This is clearly the case for chloroeremomy-
cin from A. orientalis [15] and calcium-dependent antibiotic
from S. coelicolor A3(2) (ftp://ftp.sanger.ac.uk/pub/S_coeli-
color/). While both the L- and D-isomers of p-hydroxyphen-
ylglycine are found in natural products, it is anticipated
that the L-isomer is the natural substrate of the NRPS.
Epimerization of L-p-hydroxyphenylglycine to D-p-hy-
droxyphenylglycine would occur cosynthetically as the
growing peptide translocates down the NRPS assembly
line [15]. Thus, the p-hydroxyphenylglycine biosynthetic
pathway should and does generate L-p-hydroxyphenylgly-
cine, not the D-isomer. An outline of how L-p-hydroxy-
phenylglycine biosynthesis is likely to occur was recently
suggested by the sequencing of the biosynthetic cluster for
a vancomycin group antibiotic, chloroeremomycin [15]. En-
coded within this biosynthetic cluster were four ORFs (1,
17, 21, 22) that predict a four enzyme biosynthetic pathway
beginning with the aromatic metabolite prephenate and
proceeding to L-p-hydroxyphenylglycine (Figure 2). A por-
tion of this prediction has been validated here and inde-
Figure 7. (a) Schematic representation of the ¢rst two steps of
the L-p-hydroxyphenylglycine biosynthetic pathway. (b) HPLC
traces of the following reactions: 1, p-hydroxyphenylpyruvate plus
HmaS (ORF21); 2, p-hydroxyphenylpyruvate plus Hmo (ORF22)
and 3, p-hydroxyphenylpyruvate plus HmaS and Hmo (red). Each
peak is identi¢ed by the chemical structure of the corresponding
compound.
6
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pendently by Choroba et al. in a communication which
appeared as this manuscript was being submitted [18],
demonstrating the reaction of HmaS.
HmaS
The generation of L-p-hydroxymandelate from p-hydroxy-
phenylpyruvate is the key enzymatic transformation of the
L-p-hydroxyphenylglycine biosynthetic pathway. The de-
carboxylation and hydroxylation activity of HmaS shows
novel and distinct regioselectivity, compared to all other
known p-hydroxyphenylpyruvate dioxygenases, by hy-
droxylating the benzylic position of the substrate instead
of the phenyl ring, attendant with acetate side chain mi-
gration. The independent results of Choroba et al. have
con¢rmed ORF21 is in fact a dioxygenase by 18O2 incor-
poration studies [18]. It is likely that the p-hydroxyphenyl-
pyruvate substrate is oriented subtly different towards the
Fe2-O2 in the active site. Consistent with this proposal,
alignment of HmaS with the P. £uorescens p-hydroxyphen-
ylpyruvate dioxygenase, which has been crystallized and
the structure solved [17], suggests that residues surround-
ing the opposing face of the 2-his-1-carboxylate iron-coor-
dinating residues are not conserved between the two
enzymes (data not shown). We have also established that
the benzylic hydroxylation is stereospeci¢c and yields the
L-hydroxyisomer of p-hydroxymandelate by coupling the
HmaS reaction with the next enzyme of the biosynthetic
pathway, Hmo, to generate the biosynthetic intermediate
p-hydroxybenzoylformate.
Hmo
We have established that Hmo (previously ORF22) is the
L-p-hydroxymandelate oxidase, catalyzing the formation of
p-hydroxybenzoylformate. Hmo shares amino acid se-
quence homology with GOs and MDHs. MDH is a mem-
brane bound enzyme while GO is found in the cytosol of
the cell. Sequence comparison of Hmo with GO and MDH
show that Hmo is missing the membrane anchoring se-
quence of MDH and should therefore be present in the
cytosol.
Figure 9. HPLC of the HpgT catalyzed reaction in the
biosynthetic direction. A: Authentic p-hydroxyphenylglycine.
B: Authentic L-tyrosine. C: Authentic p-hydroxymandelate.
D: Reaction consisting of D,L-p-hydroxymandelate, Hmo, L-tyrosine
and HpgT showing the formation of p-hydroxybenzoylformate and
L-p-hydroxyphenylglycine.
Figure 8. (a) HpgT catalyzed interconversion of p-hydroxy-
benzoylformate and L-tyrosine with p-hydroxyphenylpyruvate and
L-p-hydroxyphenylglycine. (b) HPLC of the HpgT catalyzed
reaction. A: Authentic p-hydroxyphenylglycine. B: Authentic
p-hydroxyphenylpyruvate. C: Authentic L-tyrosine. D: Reaction of
HpgT with D-p-hydroxyphenylglycine and p-hydroxyphenylpyruvate
showing no reaction. E: Reaction of HpgT with L-p-hydroxy-
phenylglycine and p-hydroxyphenylpyruvate showing the formation
of L-tyrosine.
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The FMN present in Hmo was susceptible to displace-
ment from the enzyme in high salt conditions. Either pu-
ri¢cation of Hmo in high salt or incubation of the enzyme
in high salt buffers gives irreversible loss of FMN and
concomitant loss of catalytic activity. We were able to over-
come this problem using a single step, amylose resin,
puri¢cation of the MBP fused protein. The protein was
frozen immediately and retained its activity for at least
3 months.
HpgT
We have demonstrated that p-hydroxybenzoylformate (the
product of the Hmo catalyzed reaction) is converted to L-p-
hydroxyphenylglycine by HpgT. HpgT shows amino acid
sequence homology to other amino acid transaminases.
Amino transferases usually use glutamate, aspartate or ala-
nine as amino donors. In a sequence comparison of known
amino transferases, the proteins cluster into three groups
depending on the amino donor they utilize (glutamate,
aspartate or alanine), however, HpgT appears to be distinct
from these enzymes (data not shown). This ¢nding gives
insight into the possibility of an unusual amino donor for
the conversion of p-hydroxybenzoylformate to L-p-hydroxy-
phenylglycine. L-Tyrosine was assayed and found to be the
amino donor for the HpgT catalyzed reaction.
The use of L-tyrosine as a cosubstrate in the reductive
amination of p-hydroxybenzoylformate to L-p-hydroxyphen-
ylglycine makes an economical pathway: as p-hydroxy-
benzoylformate is transaminated to the desired non-pro-
teinogenic amino acid L-p-hydroxyphenylglycine, the L-
tyrosine yields one equivalent of p-hydroxyphenylpyruvate
to serve as a substrate for HmaS and primes the three
enzyme cycle of HmaS, Hmo and HpgT for another
Table 1
Assay for the substrate speci¢city elicited by HpgT.
Amino acceptor Amino Donor Keto acid product Amino product
p-Hydroxybenzoylformate L-Tyr p-hydroxyphenylpyruvate Hpg
p-Hydroxyphenylpyruvate L-Hpg p-hydroxybenzoylformate Tyr
p-Hydroxyphenylpyruvate D-Hpg no reaction no reaction
Benzoylformate L-Tyr p-hydroxyphenylpyruvate Phe
p-Hydroxyphenylpyruvate L-Phg benzoylformate Tyr
p-Hydroxybenzoylformate 3-Cl-L-Tyr 3-Cl-HPP Hpg
p-Hydroxybenzoylformate L-Phe phenylpyruvate Hpg
HPP = hydroxyphenylpyruvate; Hpg = p-hydroxyphenylglycine.
Figure 10. Catalytic cycle for the
biosynthesis of L-p-hydroxyphenylglycine.
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turn. This proposal is in agreement with the prior tyrosine
labeling studies that suggested tyrosine is a p-hydroxyphen-
ylglycine precursor for vancomycin group antibiotics [11^
14]. Additionally, it is presumed that prephenate dehydro-
genase also serves to prime the biosynthetic pathway by
generating p-hydroxyphenylpyruvate from the aromatic
amino acid precursor prephenate.
The strongest in vivo support for this proposed p-hydroxy-
phenylglycine biosynthetic pathways comes from
[14C]tyrosine incorporation into the antibiotic nocardicin
A [20]. In this L-lactam antibiotic, two molecules of p-hy-
droxyphenylglycine are incorporated into the ¢nal product.
Through the use of [14C]tyrosine feeding experiments,
Hosoda et al. isolated [14C]-labeled p-hydroxymandelate,
p-hydroxybenzoylformate and p-hydroxyphenylglycine
and proposed a p-hydroxyphenylglycine biosynthetic path-
way that is nearly identical to the pathway proposed here
[20]. Therefore, it is anticipated homologs for the enzymes
discussed here will also be found in the biosynthetic clus-
ters of nocardicin antibiotics.
Signi¢cance
We have presented the initial biochemical analysis of three
ORFs from the chloroeremomycin biosynthetic cluster of
A. orientalis. Analysis of ORF21 (HmaS) shows the enzyme
is a novel non-heme iron dioxygenase that catalyzes the
synthesis of L-p-hydroxymandelate from p-hydroxyphenyl-
pyruvate. The L-p-hydroxymandelate generated by HmaS
is subsequently converted to L-p-hydroxyphenylglycine via
ORF22 (Hmo) catalyzed conversion of L-p-hydroxymande-
late to L-p-hydroxybenzoylformate followed by ORF17
(HpgT) catalyzed transamination of p-hydroxybenzoylfor-
mate to p-hydroxyphenylglycine. The biosynthesis of L-p-
hydroxyphenylglycine is proposed to be a catalytic cycle
initiated by the production of p-hydroxyphenylpyruvate.
ORF1, a homolog to prephenate dehydrogenase, present
in the gene cluster could prime the ¢rst turn of the cata-
lytic cycle (Figure 8). The conversion of prephenate to
p-hydroxyphenylpyruvate initiates the cycle and starts the
net £ux of L-tyrosine to L-p-hydroxyphenylglycine. It is
also noted that homologs of the ORFs 1, 17, 21 and 22
are also found in the biosynthetic clusters of complestatin
from S. lavendulae (Chiu and Khosla, personal communica-
tion), A47934 from S. toyocaensis (Wright, personal commu-
nication), and calcium-dependent antibiotic from S. coeli-
color A3(2) (ftp://ftp.sanger.ac.uk/pub/S_coelicolor/), all
synthesizing natural products that contain p-hydroxyphen-
ylglycine. This ¢nding suggests this four gene cluster is an
L-p-hydroxyphenylglycine biosynthetic ‘cassette’ that will
be found in all microorganisms incorporating p-hydroxy-
phenylglycine into an NRPS synthesized natural product.
Materials and methods
Cloning of ORF1 and ORF21
The proposed coding regions for ORF1 and ORF21 of the chloroeremo-
mycin cluster were ampli¢ed by polymerase chain reaction (PCR) from
A. orientalis genomic DNA with primers ORF1NtermNdeI (5P GGGAAT-
TCCATATGGAGAAGGTGCTCGTTGTCGGC 3P and ORF1CtermXhoI
(5P GGGCCGCTCGAGTCAGCGGGGACAACCCTGGGACCG 3P) for
ORF1 and ORF21NtermNdeI (5P GGGAATTCCATATGCAGAATTTC-
GAGATCGACTAC 3P) and ORF21CtermXhoI (5P GGGCCGCTCGAGT-
CATCGCCGAGCGGCGCCGAACTC 3P) for ORF21. The introduced
NdeI and XhoI restriction sites of each primer are identi¢ed by bold-
face type. The ampli¢ed products were gel puri¢ed, digested with
NdeI and XhoI and ligated, independently, into the NdeI/XhoI cloning
sites of pET16b. The resulting plasmids, pH10-ORF1 and pH10-ORF21,
introduced an in-frame His 10 af¢nity tag onto the amino terminus of
each ORF. For overexpression of ORF1 and ORF21, the af¢nity-tagged
plasmids were transformed into E. coli strain BL21(DE3). Af¢nity-tagged
ORF1 overexpressed at 30, 25 and 15³C but was not soluble under
these expression conditions.
Overexpression and puri¢cation of ORF21
The af¢nity-tagged ORF21 was overexpressed by inoculating 1 l of
Luria^Bertani (LB) broth containing 100 Wg/ml ampicillin (in a 3 l Belco
baf£ed £ask) with 10 ml of an overnight culture of BL21(DE3)/pH10-
ORF21 and growing the culture for 16 h at 30³C. Cells were harvested
by centrifugation (10 min at 5000Ug) and resuspended in 40 ml of
1UBind Buffer (20 mM Tris^HCl pH 7.9; 0.5 M NaCl; 5 mM imidazole).
Resuspended cells were broken by sonication (Fisher 550 Sonic Dis-
membrator, power = 5, 10 min sonication with 2 s on, 2 s off) and cell
debris was removed by centrifugation (30 min at 95 800Ug). ORF21
was puri¢ed by nickel chelate chromatography using HisWBind0 Resin
(Novagen). After 2 h incubation with cell-free extract, resin was packed
into a column and washed with 10 column volumes of 1UBind Buffer
followed by 10 column volumes of 1UWash Buffer (20 mM Tris^HCl pH
7.9; 0.5 M NaCl; 60 mM imidazole). Both column washes and ORF21
elution were performed at a £ow rate of 1 ml/min. ORF21 was eluted
with a linear gradient (12 column volumes) from 1UWash Buffer to
1UElution Buffer (20 mM Tris^HCl pH 7.9; 0.5 M NaCl; 0.5 M imida-
zole). The elution of ORF21 was followed via SDS^PAGE and fractions
containing ORF21 were pooled and dialyzed against Buffer A (50 mM
Tris^HCl, pH 7.9, at 4³C; 0.1 M NaCl; 5% (v/v) glycerol; 1 mM EDTA)
followed by dialysis against Buffer B (50 mM Tris^HCl, pH 7.9, at 4³C;
0.1 M NaCl; 5% (v/v) glycerol; 1 mM DTT). Dialyzed protein was con-
centrated to 2.5 mg/ml using a Centriprep 10 (Amicon), £ash-frozen in
liquid nitrogen and stored at 380³C. The protein concentration was
determined spectrophotometrically at 280 nm using the calculated molar
extinction coef¢cient of 18 610 M31 cm31. The yield of ORF21, after
puri¢cation, was 10 mg/l.
HPLC assay of ORF21
Reconstitution of holo-ORF21 involved diluting apo-ORF21 into Buffer B
containing 1 mM FeCl2. Standard reconstitution involved a 20-fold molar
excess of FeCl2 compared to enzyme. Reaction conditions were a minor
modi¢cation of those described for HPPD analysis [21]. The reaction
mixture (150 Wl), at a pH of 7.5, contained 0.8 M potassium phosphate,
0.2 M Tris^HCl, 25 mM ascorbic acid, 0.1 mg/ml bovine liver catalase,
2 WM ORF21 and additions as indicated in Figure 4. Reactions were
incubated at 25³C for 1 h and stopped by the addition of 15 Wl of
tri£uoroacetic acid (TFA). Samples were then centrifuged at 13 000
rpm for 10 min to remove denatured protein.
Products and reactants of the reaction mixtures were separated via
HPLC (Beckman System Gold) using a Vydac1 Protein and Peptide
C18 column at a £ow rate of 1 ml/min. The solvents used were as
follows: solvent A (ddH20, 0.1% TFA) and solvent B (acetonitrile,
0.1% TFA). 50 Wl of each reaction mixture was injected for each run.
The pro¢le for separation was 1 min isocratic development at 100%
A/0% B; 30 min linear gradient from 100% A/0% B to 80% A/20% B.
The elution of reaction components was monitored at 230 nm.
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Cloning, expression and puri¢cation of ORF22/pET-16b
The proposed coding regions for ORF22 of the chloroeremomycin clus-
ter was ampli¢ed by PCR from A. orientalis genomic DNA with primers
ORF22NtermNdeI (5P GGGAATTCCATATGACGTACGTTTCCCTGGC-
CGAC 3P) and ORF22CtermXhoI (5P GGGCCGCTCGAGTCAAACAAC-
CCCCAGTTTCGTGTT 3P). The introduced NdeI and XhoI restriction
sites of each primer are identi¢ed by bold-face type. The ampli¢ed prod-
ucts were gel puri¢ed, digested with NdeI and XhoI, and ligated, into the
NdeI/XhoI cloning sites of pET16b, which encodes for an N-terminal
deca-histidyl tag. Growth of ORF22/pET-16b involved inoculation of
1.5 l of LB with 50 mg/ml ampicillin (in a 3 l Belco baf£ed £ask) with
5 ml of an overnight culture. The culture was grown at 37³C for 18 h.
The cells were harvested by centrifugation (20 min at 5000Ug). Cell
pellets were resuspended in 20 ml of Binding Buffer (20 mM Tris^HCl
pH 8.0, 500 mM NaCl, 10 mM imidazole) and sonicated on a 550 Sonic
Dismembrator (Fisher Scienti¢c) (power = 5, 15 min sonication, 2 s on,
2 s off).
The cell lysates were centrifuged (45 min at 10 000Ug) and loaded on a
nickel chelating Sepharose fast £ow (Pharmacia) column preequilibrated
with Charge Buffer (20 mM Tris^HCl pH 8.0, 100 mM NaCl, 50 mM
nickel sulfate) (150 ml) and Binding Buffer (20 mM Tris^HCl pH 8.0,
500 mM NaCl, 10 mM imidazole) (150 ml). Cell lysates were loaded
onto the column at 1 ml/min. The column was then washed at 5 ml/min
with 200 ml of Binding Buffer, 200 ml of Wash Buffer (20 mM Tris^HCl
pH 8.0, 500 mM NaCl, 80 mM imidazole) and 150 ml of Binding Buffer.
The protein was eluted at 5 ml/min with 300 ml of Strip Buffer (40 mM
Tris^HCl pH 8.0, 500 mM NaCl, 100 mM EDTA). The protein was dia-
lyzed in 10 ml Tris^HCl pH 7.5, 10 mM NaCl and assayed for activity.
Cloning, expression and puri¢cation of ORF22/MBP
ORF22 was cloned via PCR into the NdeI and XhoI sites of pIADL-16
(Walsh lab vector encoding an N-terminal MBP fusion under the control
of the T7 promoter; a derivative of pET-28b). Cloning was performed
analogous to that for ORF22/pET-16b. Growth of ORF22/MBP involved
inoculation of 1.5 l of LB with 50 Wg/ml kanamycin (in a 3 l Belco baf£ed
£ask) with 5 ml of an overnight culture. The culture was grown at 37³C
for 18 h. The cells were harvested by centrifugation (20 min at 5000Ug).
Cell pellets were resuspended in 20 ml of Amylose A Buffer (10 mM
Tris^HCl pH 7.5, 10 mM NaCl) and sonicated on a 550 Sonic Dismem-
brator (Fisher Scienti¢c) (power = 5, 15 min sonication, 2 s on, 2 s off).
Cell lysates were centrifuged (45 min at 10 000Ug) and loaded onto an
Amylose resin column, preequilibrated with 150 ml 10 mM Tris^HCl pH
7.5, 10 mM NaCl. The cell lysate was loaded at 1 ml/min. The column
was washed at 2 ml/min with 300 ml Amylose A Buffer. The protein was
eluted from the column at 2 ml/min with 200 ml Amylose B Buffer (10
mM Tris^HCl pH 7.5, 10 mM NaCl, 10 mM maltose).
Spectrophotometric assay of ORF22
A typical reaction of ORF22 consisted of 15 mM Tris pH 7.5, 10 mM
NaCl, 0.1 mM potassium ferricyanide and 1 mM substrate of interest.
The decrease in the UV/Vis absorbance at 400 nm, resulting from elec-
tron transfer to the potassium ferricyanide was monitored over time.
HPLC assay of ORF22
All HPLC reactions were analyzed on a Beckman System Gold HPLC
using a Vydac1 C18 Small Pore column. The solvent system for the
analysis of the Hmo reaction used solvent A and solvent B (as above).
The pro¢le for separation was 9 min isocratic development at 100%
A/0% B, 15 min linear gradient from 100% A/0% B to 85% A/15% B.
The column was then washed with 100% B and reequilibrated with
100% A. The £ow rate for the pro¢le was 1 ml/min.
Reactions of Hmo were performed as follows. 100 Wl of Hmo (1 mg/ml)
was added to a reaction consisting of 1 mM of the desired substrate in
20 mM Tris^HCl, pH 7.5. The reactions were allowed to incubate at
25³C for 24 h. The samples were acidi¢ed with TFA to precipitate the
protein and protonate the carboxylate containing compounds. The reac-
tions were then loaded (100 Wl) using a Beckman System Gold 640
autosampler and run using the above conditions.
HPLC assays for the coupling of the ORF21 and ORF22
reactions
The reaction mixture (200 Wl), at a pH of 7.5, contained 0.8 M potassium
phosphate, 0.2 M Tris^HCl, 25 mM ascorbic acid, 0.1 mg/ml bovine liver
catalase, 500 WM p-hydroxyphenylpyruvate, and 2 WM ORF21 and/or 85
Wg of MBP-ORF22. Reactions were incubated at 25³C for either 1 h in
the presence of ORF21 or ORF22 alone, or 2 h when both enzymes
were included in the reaction mixtures. HPLC separation of products
and reactants was as described for ORF22 characterization.
Cloning, expression and puri¢cation of ORF17/MBP
The proposed coding regions for ORF217 of the chloroeremomycin
cluster was ampli¢ed by PCR from A. orientalis genomic DNA with prim-
ers ORF17NtermNdeI (5P GGGAATTCCATATGGAAATCCTAGTATTC-
ATGGAT 3P) and ORF17CtermNdeI (5P GGGCCGCATATGTTATGCC-
CGGGGCCACCGCAGACG 3P). The introduced NdeI restriction sites of
each primer are identi¢ed by bold-face type. The ampli¢ed products
were gel puri¢ed, digested with NdeI, and ligated, into the NdeI cloning
sites of pIADL-16 (Walsh lab vector encoding an N-terminal MBP fusion
under the control of the T7 promoter; a derivative of pET-28b). The
growth of ORF17/MBP involved inoculation of 1.5 l of LB with 50
Wg/ml kanamycin (in a 3 l Belco baf£ed £ask) with 5 ml of an overnight
culture. The culture was grown at 37³C for 18 h. The cells were har-
vested by centrifugation (20 min at 5000Ug). Cell pellets were resus-
pended in 20 ml of Amylose A Buffer and sonicated on a 550 Sonic
Dismembrator (Fisher Scienti¢c) (power = 5, 15 min sonication, 2 s on,
2 s off).
Cell lysates were centrifuged (45 min at 10 000Ug) and loaded onto an
Amylose resin column, preequilibrated with 150 ml 10 mM Tris^HCl pH
7.5, 10 mM NaCl. The cell lysate was loaded at 1 ml/min. The column
was washed at 2 ml/min with 300 ml Amylose A Buffer. The protein was
eluted from the column at 2 ml/min with 200 ml Amylose B Buffer.
HPLC assay of ORF17
All HPLC reactions were analyzed on a Beckman System Gold HPLC
using a Vydac1 C18 small pore column. The solvent system for the
analysis of the Hmo reaction used solvent A and solvent B. The pro¢le
for separation was 9 min isocratic development at 100% A/0% B, 15 min
linear gradient from 100% A/0% B to 85% A/15% B. The column was
then washed with 100% B and reequilibrated with 100% A. The £ow rate
for the pro¢le was 1 ml/min.
Reactions of HpgT were performed as follows. One hundred Wl of HpgT
(1 mg/ml) was added to a reaction consisting of 1 mM of the amino
donor and 1 mM of the amino acceptor and 10 WM of PLP in 20 mM Tris
pH 7.5. (In the case where p-hydroxybenzoylformate was the desired
amino acceptor, p-hydroxymandelate was used as the amino acceptor
and 100 Wl of Hmo (1 mg/ml) was included in the reaction.) The reac-
tions were allowed to incubate at 25³C for 24 h. The samples were
acidi¢ed with TFA to precipitate the protein and protonate the carbox-
ylate containing compounds. The reactions were then loaded using an
autosampler using the above conditions.
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